Madrigal Pharmaceuticals, Inc. MDGL Other Non-Current Assets

Other Non-Current Assets at other companies

Eli LillyLLY

$7.23B+19.0%

Arrowhead ResearchARWR

$4.89M+272%

Segments

By geography

See full

West Conshohocken, Pennsylvania$4M—

Other financials

Income statement

See full

Revenue$311.3M+127%

Gross profit$43.5M—

Operating income-$92.7M-16.9%

Net income-$94.4M-28.9%

EPS (diluted)-$3.25-24.5%

Balance sheet

See full

Cash & equivalents$232.2M+23.1%

Total debt$377.3M+187%

Total equity$543.5M-23.5%

Total assets$1.2B+23.1%

Cash flow

See full

Operating cash flow-$167.4M-88.4%

CapEx$3.8M—

Free cash flow-$171.3M-92.7%

Valuation

See full

Market cap$11.66B+64.2%

Enterprise value$11.81B+67.5%

P/S10.3×-12.1×

Profitability

See full

Gross margin96.5%—

Operating margin-27.7%-12.2pp

Net margin-27.3%-12.0pp

FCF margin-59.8%-29.6pp

Returns & leverage

See full

Return on equity-49.3%-0.8pp

Debt / equity0.7×+0.5×

Current ratio3.5×-2.4×

Where this comes from

Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Madrigal Pharmaceuticals, Inc.'s other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Madrigal Pharmaceuticals, Inc.'s other non-current assets?: Madrigal Pharmaceuticals, Inc. (MDGL) reported other non-current assets of $23.5M in Q1 2026.